Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'

Haemophilia. 2015 Nov;21(6):e489-92. doi: 10.1111/hae.12754. Epub 2015 Jul 14.

Authors

A D Shapiro¹, S Li²

Affiliations

¹ Department of Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.
² Biogen, Cambridge, MA, USA.

PMID: 26173031
DOI: 10.1111/hae.12754

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Factor VIII / pharmacokinetics*
Factor VIII / therapeutic use*
Hemophilia A / drug therapy*
Humans
Male
Premedication*
Recombinant Proteins*

Substances

Recombinant Proteins
Factor VIII